Medical experts are raising alarms over Respiratory Syncytial Virus (RSV), a major yet overlooked cause of serious respiratory infections in Indian infants. With India’s large birth rate, RSV contributes significantly to global child hospitalizations and deaths—especially during monsoon and early winter.Pediatricians emphasize that while hygiene helps, newer preventive tools like monoclonal antibodies are key. The WHO-backed Nirsevimab, a single-dose seasonal antibody, now offers broad protection. Experts stress urgent awareness, access, and timely immunization to reduce RSV’s toll and protect India’s youngest population.
Dr. Vasant M. Khalatkar, National President, Indian Academy of Pediatrics (IAP): “RSV is a major threat to infants. With new long-acting antibodies like Nirsevimab, we can now offer stronger, season-long protection and reduce hospitalizations.”
Dr. Bhavesh Kotak, Head, Medical Affairs, Dr. Reddy’s: “India faces a heavy RSV burden. Greater awareness and access to preventive immunization are key to saving young lives.”